Genomictree Inc. (KOSDAQ:228760)

South Korea flag South Korea · Delayed Price · Currency is KRW
13,030
+290 (2.28%)
May 30, 2025, 3:30 PM KST
-36.44%
Market Cap 312.78B
Revenue (ttm) 2.39B
Net Income (ttm) -10.50B
Shares Out 24.00M
EPS (ttm) -432.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 122,362
Average Volume 88,155
Open 12,960
Previous Close 12,740
Day's Range 12,900 - 13,540
52-Week Range 12,010 - 26,000
Beta 0.09
RSI 37.63
Earnings Date May 13, 2025

About Genomictree

Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraDTect SARS-CoV-2 RT-qPCR... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 228760
Full Company Profile

Financial Performance

In 2024, Genomictree's revenue was 2.36 billion, a decrease of -30.89% compared to the previous year's 3.42 billion. Losses were -10.24 billion, 17.0% more than in 2023.

Financial Statements

News

There is no news available yet.